Analysis of PADA-1 Trial Highlights Kinetics and Determinants of ESR1 Mutations in HR+/HER2– Metastatic Breast Cancer
Image Credit: Maris – stock.adobe.com
An analysis from the phase 3 PADA-1 trial (NCT03079011) examining the kinetics and determinants of ESR1 mutations detected in the blood of patients with hormone receptor–positive, HER2-negative metastatic breast cancer showed that the incidence of these emerging alterations was uneven over time.1
Findings presented at the 2025 ESMO Breast Congress demonstrated that the incidence of ESR1 mutations mirrored a bell-shaped curve, with fewer mutations detected before 6 months and after 30 months compared with patients who experienced disease progression without the emergence of an ESR1 mutation.
A multivariate analysis examining factors modulating the relative incidence of ESR1 mutations showed that…
